[
  {
    "ts": "2026-02-23T06:07:15+00:00",
    "headline": "How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations",
    "summary": "Analysts have adjusted their fair value estimate for PTC Therapeutics slightly lower, from US$88.50 to about US$87.93, keeping price targets clustered in the low to mid US$80s. This small move reflects how recent Street research is balancing optimism around Sephience with caution on DMD pressure and longer term growth visibility. As you read on, you will see how these shifting targets and narratives might shape how you follow PTC from here. Stay updated as the Fair Value for PTC Therapeutics...",
    "url": "https://finance.yahoo.com/news/sephience-reshaping-story-ptc-therapeutics-060715713.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cae2212f-04ef-310d-b6f7-a76157eb4f19",
      "content": {
        "id": "cae2212f-04ef-310d-b6f7-a76157eb4f19",
        "contentType": "STORY",
        "title": "How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations",
        "description": "",
        "summary": "Analysts have adjusted their fair value estimate for PTC Therapeutics slightly lower, from US$88.50 to about US$87.93, keeping price targets clustered in the low to mid US$80s. This small move reflects how recent Street research is balancing optimism around Sephience with caution on DMD pressure and longer term growth visibility. As you read on, you will see how these shifting targets and narratives might shape how you follow PTC from here. Stay updated as the Fair Value for PTC Therapeutics...",
        "pubDate": "2026-02-23T06:07:15Z",
        "displayTime": "2026-02-23T06:07:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sephience-reshaping-story-ptc-therapeutics-060715713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sephience-reshaping-story-ptc-therapeutics-060715713.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PTCT"
            },
            {
              "symbol": "PTC"
            },
            {
              "symbol": "BAC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]